RESUMEN
OBJECTIVE: Evaluate if statin therapy prior to elective coronary stent implantation (CSI) reduces the plasma levels of markers of inflammation and of myocardial necrosis in low-risk stable coronary artery disease patients (CAD). BACKGROUND: The elevation of markers of inflammation and of myocardial necrosis after percutaneous coronary intervention may interfere with clinical outcome. Among acute coronary syndrome patients, statins improve clinical outcomes when used before CSI-mostly due to reduction of CSI-related myocardial infarction. However, little is known concerning preprocedural statin therapy on the reduction of these markers in stable patients at low-risk. METHODS: In this prospective, observational study, 100 patients (n = 50 on statin therapy vs. n = 50 not on statin) with stable coronary artery disease underwent elective CSI. Inflammatory (C-reactive protein [CRP], interleukin [IL]-6, tumor necrosis factor-α and matrix metalloproteinase-9) and myocardial necrosis markers (troponin I and CK-MB) were determined before and 24 hr after CSI. RESULTS: All patients presented a significant increase of CRP and IL-6 after CSI. However, this increase was attenuated in patients on statin therapy prior to CSI than those without statin therapy: 75% vs. 150% (P < 0.001) and 192% vs. 300% (P < 0.01). The other pro-inflammatory markers were similar for both sets of patients. Troponin I and CK-MB did not change after CSI regardless of previous statin therapy or not. CONCLUSIONS: Pretreatment with statin attenuates procedural inflammation, denoted by markedly lower increases of CRP and IL-6 levels, in elective CSI within low-risk stable CAD patients. Periprocedural myocardial injury was irrelevant and was not affected by preprocedural statin therapy in this population.
Asunto(s)
Antiinflamatorios/uso terapéutico , Enfermedad de la Arteria Coronaria/terapia , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Mediadores de Inflamación/sangre , Miocardio/metabolismo , Intervención Coronaria Percutánea/instrumentación , Stents , Anciano , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Enfermedad de la Arteria Coronaria/diagnóstico , Forma MB de la Creatina-Quinasa/sangre , Femenino , Humanos , Interleucina-6/sangre , Masculino , Persona de Mediana Edad , Miocardio/patología , Necrosis , Intervención Coronaria Percutánea/efectos adversos , Estudios Prospectivos , Factores de Riesgo , Resultado del Tratamiento , Troponina I/sangreAsunto(s)
Síndrome Coronario Agudo/tratamiento farmacológico , Colesterol/sangre , Combinación Ezetimiba y Simvastatina/administración & dosificación , Ezetimiba/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Síndrome Coronario Agudo/sangre , Síndrome Coronario Agudo/epidemiología , Anticolesterolemiantes/administración & dosificación , Brasil/epidemiología , Relación Dosis-Respuesta a Droga , Humanos , Incidencia , Resultado del TratamientoRESUMEN
PURPOSE: Patients with acute myocardial infarction (AMI) and respiratory impairment may be treated with either invasive or non-invasive mechanical ventilation (MV). However, there has been little testing of non-invasive MV in the setting of AMI. Our objective was to evaluate the incidence and associated clinical outcomes of patients with AMI who were treated with non-invasive or invasive MV. METHODS: This was a retrospective observational study in which consecutive patients with AMI (n = 1610) were enrolled. The association between exclusively non-invasive MV, invasive MV and outcomes was assessed by multivariable models. RESULTS: Mechanical ventilation was used in 293 patients (54% invasive and 46% exclusively non-invasive). In-hospital mortality rates for patients without MV, with exclusively non-invasive MV, and with invasive MV were 4.0%, 8.8%, and 39.5%, respectively (P<0.001). The median lengths of hospital stay were 6 (5.8-6.2), 13 (11.2-4.7), and 28 (18.0-37.9) days, respectively (P<0.001). Exclusively non-invasive MV was not associated with in-hospital death (adjusted HR = 0.90, 95% CI 0.40-1.99, P = 0.79). Invasive MV was strongly associated with a higher risk of in-hospital death (adjusted HR = 3.07, 95% CI 1.79-5.26, P<0.001). CONCLUSIONS: In AMI setting, 18% of the patients required MV. Almost half of these patients were treated with exclusively non-invasive strategies with a favorable prognosis, while patients who needed to be treated invasively had a three-fold increase in the risk of death. Future prospective randomized trials are needed to compare the effectiveness of invasive and non-invasive MV for the initial approach of respiratory failure in AMI patients.
Asunto(s)
Infarto del Miocardio/terapia , Respiración Artificial , Insuficiencia Respiratoria/terapia , Anciano , Anciano de 80 o más Años , Femenino , Mortalidad Hospitalaria , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Infarto del Miocardio/mortalidad , Pronóstico , Insuficiencia Respiratoria/mortalidad , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
We report the case of a 73-year-old male patient who was a candidate for correction of an abdominal aortic aneurysm without abnormalities in his first cardiological evaluation. The surgery was postponed because of the need for treatment of epididymitis. Two weeks later, the patient returned to the hospital with thoracic pain, when the angiography showed obstructions in 2 coronary arteries, which were successfully treated with percutaneous transluminal angioplasty and stent implantation. After 45 days, the patient underwent surgery for correction of the abdominal aortic aneurysm under peridural and general anesthesia. The patient evolved without complications.
Asunto(s)
Aneurisma de la Aorta Abdominal/cirugía , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Cuidados Preoperatorios , Anciano , Dipiridamol , Humanos , Masculino , Cintigrafía , Radiofármacos , Índice de Severidad de la Enfermedad , Tecnecio Tc 99m SestamibiRESUMEN
BACKGROUND: Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether therapeutic uptitration with different lipid-lowering strategies has a similar "pleiotropic" effect on atherosclerotic endothelial dysfunction evaluated by measurement of endothelial progenitor cells (EPCs). OBJECTIVE: We sought to compare, in patients with stable CAD and with a low-density lipoprotein cholesterol (LDL-C) >70 mg/dL on treatment with simvastatin 20 mg, the effects on EPCs by increasing simvastatin to 80 mg versus adding ezetimibe 10 mg. METHODS: Patients (n = 68, 63 ± 9 years, 39% men) were randomly allocated to receive ezetimibe 10/simvastatin 20 mg or simvastatin 80 mg for 6 weeks. Circulating EPCs were measured by flow cytometry before and after the treatment. RESULTS: Both strategies presented similar effects on metabolic parameters. The LDLs were equally reduced by ezetimibe 10/simvastatin 20 mg and simvastatin 80 mg (28.9% ± 13% vs 21.1% ± 33%; P = .46, respectively). The levels of EPCs were unaffected by ezetimibe 10/simvastatin 20 mg (median [25th, 75th]: pre- vs posttreatment, 7.0 [2.3; 13.3] vs 3.1 [0.1; 13.2] EPCs/10(4) mononuclear cells; P = .43) or simvastatin 80 mg (pre- vs posttreatment, 6.1 [2.9; 15.2] vs 4.0 [1.4; 10.7] EPCs/10(4) mononuclear cells; P = .5), and there were no differences between the groups on treatment effects (P = .9). CONCLUSIONS: Among stable patients with CAD and with an LDL-C >70 mg/dL on simvastatin 20 mg, increasing simvastatin dose to 80 mg or adding ezetimibe 10 mg promoted similar further cholesterol reduction but did not have incremental effects on circulating EPCs. These data suggest that the effects of simvastatin moderate doses on EPCs are not increased by intensive lipid-lowering strategies (clinicaltrials.gov: NCT00474123).
Asunto(s)
Anticolesterolemiantes/uso terapéutico , Azetidinas/uso terapéutico , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Hipercolesterolemia/tratamiento farmacológico , Simvastatina/uso terapéutico , Anciano , Anticolesterolemiantes/administración & dosificación , Anticolesterolemiantes/farmacología , Azetidinas/administración & dosificación , Azetidinas/farmacología , LDL-Colesterol/sangre , LDL-Colesterol/efectos de los fármacos , Enfermedad de la Arteria Coronaria/fisiopatología , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Combinación Ezetimiba y Simvastatina , Femenino , Citometría de Flujo , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Hipercolesterolemia/complicaciones , Masculino , Persona de Mediana Edad , Simvastatina/administración & dosificación , Simvastatina/farmacología , Células Madre/efectos de los fármacos , Células Madre/metabolismoRESUMEN
BACKGROUND: In the setting of stable coronary artery disease (CAD), it is not known if the pleiotropic effects of cholesterol reduction differ between combined ezetimibe/simvastatin and high-dose simvastatin alone. OBJECTIVE: We sought to compare the anti-inflammatory and antiplatelet effects of ezetimibe 10mg/simvastatin 20mg (E10/S20) with simvastatin 80 mg (S80). METHODS AND RESULTS: CAD patients (n=83, 63 ± 9 years, 57% men) receiving S20, were randomly allocated to receive E10/S20 or S80, for 6 weeks. Lipids, inflammatory markers (C-reactive protein, interleukin-6, monocyte chemoattractant protein-1, soluble CD40 ligand and oxidized LDL), and platelet aggregation (platelet function analyzer [PFA]-100) changes were determined. Baseline lipids, inflammatory markers and PFA-100 were similar between groups. After treatment, E10/S20 and S80 patients presented, respectively: (1) similar reduction in LDL-C (29 ± 13% vs. 28 ± 30%, p=0.46), apo-B (18 ± 17% vs. 22 ± 15%, p=0.22) and oxidized LDL (15 ± 33% vs. 18 ± 47%, p=0.30); (2) no changes in inflammatory markers; and, (3) a higher increase of the PFA-100 with E10/S20 than with S80 (27 ± 43% vs. 8 ± 33%, p=0.02). CONCLUSIONS: These data suggest that among stable CAD patients treated with S20, (1) both E10/S20 and S80 were equally effective in further reducing LDL-C; (2) neither treatment had any further significant anti-inflammatory effects; and (3) E10/S20 was more effective than S80 in inhibiting platelet aggregation. Thus, despite similar lipid lowering and doses 4× less of simvastatin, E10/S20 induced a greater platelet inhibitory effect than S80.
Asunto(s)
Anticolesterolemiantes/administración & dosificación , Azetidinas/administración & dosificación , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Hipercolesterolemia/tratamiento farmacológico , Simvastatina/administración & dosificación , Anciano , Apolipoproteínas B/sangre , Biomarcadores/sangre , LDL-Colesterol/sangre , Enfermedad de la Arteria Coronaria/sangre , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Ezetimiba , Femenino , Humanos , Hipercolesterolemia/sangre , Lipoproteínas LDL/sangre , Masculino , Persona de Mediana Edad , Agregación Plaquetaria/efectos de los fármacosRESUMEN
BACKGROUND: Previous studies have demonstrated that leukocytosis and hyperglycemia verified at the admission of patients with acute myocardial infarction (AMI) are associated with intrahospital mortality. However, little is known on the long-term impact of these markers. OBJECTIVE: To evaluate the short-and long-term influence of the levels of glucose and leukocytes on the prognosis of patients with AMI. METHODS: A total of 809 patients with AMI were retrospectively assessed (mean age: 63.2 +/- 12.87 yrs) and prospectively and consecutively included in a specific database. RESULTS: a) At the intrahospital phase, the mean values were compared between patients that died and those who survived: Leukocytosis: 12156+/-5977 vs 10337+/-3528 (p=0.004, 95%CI = 976-2663); Glucose 176+/-105 mg/dl vs 140+/-72 mg/dl (p<0.001, 95%CI = 19.4 - 52.6), respectively. b) With the adjusted mode, the same pattern was observed [p values: 0.002 (t-ratio 3.05), 0.04 (t-ratio 2.06), respectively]. c) Long-term follow-up: the univariate analysis showed P values of 0.001 (t-ratio 3.3), <0.001 (t-ratio 4.16), respectively. The multivariate analysis showed P=0.001 (t-ratio 3.35), 0.08 (t-ratio 1.75), respectively. (d) After the exclusion of the intrahospital deaths, the leukocyte (P=0.989) and glucose levels (P=0.144) did not remain significantly correlated with mortality. The same result was observed at the multivariate analysis. CONCLUSION: The levels of glucose and leukocytes at the hospital admission of patients with AMI are excellent predictors of intrahospital mortality and poor predictors of long-term death.
Asunto(s)
Mortalidad Hospitalaria , Leucocitosis/mortalidad , Infarto del Miocardio/mortalidad , Biomarcadores/sangre , Glucemia/análisis , Brasil/epidemiología , Métodos Epidemiológicos , Femenino , Humanos , Hiperglucemia/complicaciones , Hiperglucemia/mortalidad , Recuento de Leucocitos , Leucocitosis/sangre , Masculino , Persona de Mediana Edad , Infarto del Miocardio/sangre , PronósticoAsunto(s)
Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Células Endoteliales , Mediadores de Inflamación/sangre , Activación Plaquetaria/fisiología , Células Madre , Anciano , Aspirina/uso terapéutico , Biomarcadores , Proteína C-Reactiva/análisis , Enfermedad de la Arteria Coronaria/sangre , Enfermedad de la Arteria Coronaria/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de Agregación Plaquetaria/uso terapéutico , Pruebas de Función Plaquetaria , Estadísticas no Paramétricas , Factores de TiempoRESUMEN
FUNDAMENTO: Estudos prévios demonstraram que a leucocitose e a hiperglicemia verificadas à admissão de pacientes com IAM (infarto agudo do miocárdio), estão correlacionadas com a mortalidade intra-hospitalar. Entretanto, pouco é sabido sobre o impacto desses marcadores a longo prazo. OBJETIVO: Avaliar a curto e longo prazos, a influência dos níveis de glicose e leucócitos no prognóstico de pacientes com IAM. MÉTODOS: Foram analisados, retrospectivamente, 809 pacientes (idade média 63,2 ± 12,87 anos) com IAM, incluídos de forma prospectiva e consecutiva em banco de dados específico. RESULTADOS: a) Na fase intra-hospitalar os valores médios aferidos foram comparados entre pacientes que morreram ou sobreviveram: Leucocitose 12156±5977 vs 10337±3528 (p=0.004, 95 por cento IC= 976-2663); Glicose 176±105 mg/dl vs 140±72 mg/dl (p<0.001, 95 por cento IC= 19.4 - 52.6), respectivamente. b) No modo ajustado, o mesmo padrão foi verificado [valores de p: 0.002 (t-ratio 3.05), 0.04 (t-ratio 2.06), respectivamente]. c) Seguimento a longo prazo: a análise univariada revelou valores de P de 0.001 (t-ratio 3.3), <0.001 (t-ratio 4.16), respectivamente. Pela análise multivariada; P=0.001 (t-ratio 3,35), 0.08 (t-ratio 1,75), respectivamente. d) Após exclusão das mortes intra-hospitalares, os níveis leucocitários (P=0.989) e a glicemia (P=0.144) não permaneceram correlacionadas significativamente com mortalidade. O mesmo resultado foi verificado na análise multivariada. CONCLUSÃO: Níveis de leucócitos e glicemia à admissão de pacientes com IAM são excelentes preditores de mortalidade intra-hospitalar, e pobres preditores de óbitos a longo prazo.
BACKGROUND: Previous studies have demonstrated that leukocytosis and hyperglycemia verified at the admission of patients with acute myocardial infarction (AMI) are associated with intrahospital mortality. However, little is known on the long-term impact of these markers. OBJECTIVE: To evaluate the short-and long-term influence of the levels of glucose and leukocytes on the prognosis of patients with AMI. METHODS: A total of 809 patients with AMI were retrospectively assessed (mean age: 63.2 ± 12.87 yrs) and prospectively and consecutively included in a specific database. RESULTS: a) At the intrahospital phase, the mean values were compared between patients that died and those who survived: Leukocytosis: 12156±5977 vs 10337±3528 (p=0.004, 95 percentCI = 976-2663); Glucose 176±105 mg/dl vs 140±72 mg/dl (p<0.001, 95 percentCI = 19.4 - 52.6), respectively. b) With the adjusted mode, the same pattern was observed [p values: 0.002 (t-ratio 3.05), 0.04 (t-ratio 2.06), respectively]. c) Long-term follow-up: the univariate analysis showed P values of 0.001 (t-ratio 3.3), <0.001 (t-ratio 4.16), respectively. The multivariate analysis showed P=0.001 (t-ratio 3.35), 0.08 (t-ratio 1.75), respectively. (d) After the exclusion of the intrahospital deaths, the leukocyte (P=0.989) and glucose levels (P=0.144) did not remain significantly correlated with mortality. The same result was observed at the multivariate analysis. CONCLUSION: The levels of glucose and leukocytes at the hospital admission of patients with AMI are excellent predictors of intrahospital mortality and poor predictors of long-term death.
FUNDAMENTO: Estudios previos demostraron que tanto la leucocitosis como la hiperglucemia verificadas cuando de la admisión de pacientes con infarto agudo de miocardio (IAM), están correlacionadas con la mortalidad intrahospitalaria. Sin embargo, poco se sabe acerca del impacto de esos marcadores a largo plazo. OBJETIVO: Evaluar, a corto y largo plazos, la influencia de los niveles de glucosa y leucocitos en el pronóstico de pacientes con IAM. MÉTODOS: Se analizaron, retrospectivamente, a 809 pacientes (edad promedio 63,2 ± 12,87 años) con IAM, incluidos de forma prospectiva y consecutiva en banco de datos específico. RESULTADOS: a) En la fase intrahospitalaria se compararon los valores promedio obtenidos entre pacientes que murieron o supervivieron: leucocitosis 12.156±5.977 vs 10.337±3.528 (p=0.004, 95 por ciento IC= 976-2663); glucosa 176±105 mg/dl vs 140±72 mg/dl (p<0.001, 95 por ciento IC= 19.4 - 52.6), respectivamente. b) En el modo ajustado, se verificó el mismo estándar [valores de p: 0.002 (t-ratio 3.05), 0.04 (t-ratio 2.06), respectivamente]. c) Seguimiento a largo plazo: el análisis univariado reveló valores de P de 0.001 (t-ratio 3.3), <0.001 (t-ratio 4.16), respectivamente. Ya el análisis multivariado: P=0.001 (t-ratio 3,35), 0.08 (t-ratio 1,75), respectivamente. d) Tras la exclusión de las muertes intrahospitalarias, los niveles leucocitarios (P=0.989) y la glucemia (P=0.144) no permanecieron correlacionadas significativamente con la mortalidad. Igual resultado se verificó en el análisis multivariado. CONCLUSIÓN: Los niveles de leucocitos y glucemia al ingreso de pacientes con IAM resultan excelentes predictores de mortalidad intrahospitalaria, y pobres predictores de óbitos a largo plazo.
Asunto(s)
Femenino , Humanos , Masculino , Persona de Mediana Edad , Mortalidad Hospitalaria , Leucocitosis/mortalidad , Infarto del Miocardio/mortalidad , Biomarcadores/sangre , Glucemia/análisis , Brasil/epidemiología , Métodos Epidemiológicos , Hiperglucemia/complicaciones , Hiperglucemia/mortalidad , Recuento de Leucocitos , Leucocitosis/sangre , Infarto del Miocardio/sangre , PronósticoAsunto(s)
Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Células Endoteliales , Mediadores de Inflamación/sangre , Activación Plaquetaria/fisiología , Células Madre , Aspirina/uso terapéutico , Biomarcadores , Proteína C-Reactiva/análisis , Enfermedad de la Arteria Coronaria/sangre , Enfermedad de la Arteria Coronaria/patología , Pruebas de Función Plaquetaria , Inhibidores de Agregación Plaquetaria/uso terapéutico , Estadísticas no Paramétricas , Factores de TiempoRESUMEN
Descreve-se o caso de um paciente de 73 anos, candidato à correção de aneurisma de aorta abdominal, sem anormalidades na primeira avaliação cardiológica. A cirurgia foi postergada para tratamento de epididimite. Duas semanas após, o paciente retornou ao hospital com dor torácica e a angiografia mostrou obstruções de duas coronárias, tratadas com sucesso por angioplastia transluminal percutânea com implante de stent. Após 45 dias, o paciente foi submetido à cirurgia para correção do aneurisma de aorta abdominal sob anestesia peridural e geral, evoluindo sem complicações.